.jpeg)
2026-10-14 04:40:08
This article reviews the mechanism, indications, dosing, toxicity management, and global clinical data of Selinexor, providing an objective reference for RRMM patients.
2026-10-13 07:01:50
Acalabrutinib is a selective BTK inhibitor that covalently blocks the BTK active-site cysteine and interrupts BCR downstream signaling in CLL/SLL and related B-cell tumors. It affects malignant and normal B cells, so infection, bleeding, arrhythmia, cytopenias, and resistance pathways all require structured monitoring.
2026-10-13 06:58:10
Bosutinib is an oral BCR-ABL and SRC-family tyrosine kinase inhibitor for newly diagnosed or resistant/intolerant Philadelphia chromosome-positive chronic-phase CML in adults, resistant/intolerant accelerated or blast-phase CML in adults, and chronic-phase CML in children aged 1 year and older. Main safety work covers diarrhea, liver injury, myelosuppression, and fluid retention.
2026-10-12 06:45:08
Venetoclax is a selective BCL-2 inhibitor for adult CLL/SLL and for AML unfit for intensive chemotherapy in combination regimens. A 5-week CLL ramp to 400mg daily and a 3–4-day AML ramp reduce tumor lysis risk; myelosuppression, infections, and CYP3A interactions require structured monitoring. Some overseas markets add fixed-duration BCL-2 plus BTK first-line CLL pathways.
2026-10-09 06:37:20
In October 2026, FDA expanded pirtobrutinib (Jaypirca) for previously untreated adults with CLL/SLL and no known 17p deletion. In BRUIN CLL-313, 200mg once daily versus bendamustine plus rituximab gave median PFS not reached vs 33.5 months; manage infection, bleeding, cytopenias, arrhythmia, hepatotoxicity, and second cancers.
2026-09-28 04:52:25
Belumosudil is a ROCK2 inhibitor for chronic graft-versus-host disease in patients aged 12 years and older after inadequate response to prior systemic therapy. Use 200mg once daily with food; manage embryo-fetal risk and contraception, strong CYP3A inducers/PPI dosing changes, monthly liver tests, and infection or hypertension adverse events.
2026-09-14 03:29:24
Acalabrutinib for chronic lymphocytic leukemia/small lymphocytic lymphoma is assessed by age, stage, TP53/17p status, prior therapy, and relapse. Long-term data support progression-free survival and durable disease control rather than a fixed “added years” estimate.
2026-09-14 03:25:01
Bosutinib is used for Ph+ chronic myeloid leukemia. Symptom change in a few days does not reflect efficacy. Response is tracked by CBC, BCR-ABL quantification, and cytogenetics; molecular remission often takes months, with mutation retesting for T315I/V299L.
2026-09-14 03:16:19
Acalabrutinib is usually 100mg twice daily for CLL/SLL monotherapy or with obinutuzumab, and for transplant-ineligible newly diagnosed MCL with bendamustine plus rituximab. This guide simplifies dosing, toxicity breaks, and interactions.
2026-09-14 03:06:37
Bosutinib is a BCR-ABL and Src-family tyrosine kinase inhibitor for newly diagnosed and resistant/intolerant Philadelphia chromosome-positive chronic myeloid leukemia, covering chronic, accelerated, blast phases and pediatric chronic-phase use.
2026-09-10 02:52:45
A multicenter Ib/II trial shows the azacitidine + venetoclax + ivosidenib triplet regimen achieves 95% ORR in newly diagnosed IDH1-mutant AML with manageable safety.
2026-09-07 05:13:58
Does anagrelide worsen myelofibrosis in essential thrombocythemia (ET)? This article reviews clinical evidence, distinguishes drug effects from natural disease progression, and highlights monitoring strategies.
